– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support
Form 20-F KAZIA THERAPEUTICS LTD For: Jun 30 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Leen Farouki and colleagues discuss the global prevalence and distribution of female genital mutilation/cutting by World Health Organization region and country.
Kazia Therapeutics has busy and productive June quarter with important readouts slated for second half
All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia. Its cash position as at end June stood at A$27.6 million
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has had a “busy and productive” June quarter as it makes great strides with the paxalisib clinical program, including the launch of two new studies.
The oncology-focused drug development company is also expecting a number of important read-outs targeted for the second half of the year.
All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia.